In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Practice Guideline Track on Management of Dyslipidaemias

Guidelines Into Practice

Coronary Artery Disease (Chronic)
Cardiovascular Disease in Primary Care
Rehabilitation and Sports Cardiology
Basic Science
Cardiovascular Rehabilitation
Risk Factors and Prevention
Cardiovascular Pharmacotherapy

Contributors:  Special thanks to Professor Olov Wiklund and Professor Guy De Backer 

Based on the 2016 ESC Guidelines on Dyslipidaemias 2016 (Management of)

Webinars on this topic

 2016 ESC webinar on "ESC Guidelines on Dyslipidaemias 2016: new knowledge and tools for lipid management"  streamed live on 4 Oct 2016: Watch the recording.

Update - ESC Congress 2017

Topics in focus

Session title Slides Webcast
Individuals with increased LDL cholesterol are not treated to recommended levels: a danish registry based study    
Inflammatory processes in cardiovascular disease: a route to personalised medicine?    
Low LDL-cholesterol goal attainment 4 months after ACS due to lack of adjustment in lipid lowering treatment: Results from DYSIS II    
Lp(a): should we go after it? Should it modify our lipid targets?    
Management of hypercholesterolaemia in non-Western countries and achievement of LDL-C goals: an international, cross-sectional, observational study    
Rate of cholesterol goal attainment in patients with coronary heart disease: Results from the Dyslipidemia International Study II    
Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition    
State of the Art: cholesterol-lowering therapy for primary and secondary prevention    
When to start preventive therapy - Best way forward? What do the Guidelines say?    
Biochemical markers of muscle damage in women and men treated with statins.    
Biomarkers to identify at-risk individuals.    
Cascade screening for familial hypercholesterolaemia    
Changes in lipid-lowering therapy prescription patterns following a second cardiovascular disease event    
Changing to a healthy diet - What do the guidelines say?    
Changing to a healthy diet. How to implement Guidelines – Panel discussion    
Cholesterol metabolism and the role of PCSK9    
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial    
Comparison of the low-density lipoprotein cholesterol target value and the preventive effect of statins in elderly patients and younger patients    
Diet in patients with metabolic syndrome - Low carb or low cholesterol?    
"Precision medicine" and primary prevention.    
"Statins for life"? The effect of statins on survival in primary prevention.    
A global view: the rationale for aggresive LDL lowering    
A simple screening model for type 2 diabetes in primary care patients treated for hypertension or dyslipidemia a report from EUROASPIRE IV a survey from the european society of cardiology    
Adherence to PCSK9 inhibitors in high cardiovascular risk patients in real-world setting: results from a single-center experience and comparison with statin therapy.    
Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease using clinical trial evidence: results from the prospective population-based Rotterdam Study    
Assessment of absolute reductions in LDL-C associated with alirocumab therapy: results from across the Phase 3 ODYSSEY programme    
Association between high-density lipoprotein cholesterol and all-cause mortality in general population    
Association of high intensity statin with lower mortality in Asian patients with acute myocardial infarction    
Associations between very low concentrations of LDL-cholesterol and health outcomes in the reasons for geographical and racial differences in stroke (REGARDS) Study    
Differences in recommendations and associated level of evidence for statins in primary prevention of CVD according to the ACC/AHA 2013, CCS 2016, ESC 2016, and USPSTF 2016 clinical practice guidelines    
Discussant review: Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study    
Does intensive treat-to-target LDL-C lowering therapy using statin in patients of diabetic retinopathy reduce cardiovascular events?: the EMPATHY study    
Effects of morning versus evening statin therapy on lipid profile: A systematic review and meta-analysis    
Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes    
Evaluation of coronary artery calcium score for statin treatment strategy according to ESC guidelines in asymptomatic asian adults    
Ideal timing of cholesterol lowering in primary prevention: should we start earlier?    
Impact of CETP inhibition with evacetrapib in patients with diabetes mellitus: results from ACCELERATE    
Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1    
Impact of the european and american guidelines on the management and treatment of dyslipidemia in a spanish working population    


ESC Congress 2016

Part 1 - Overview of the Guidelines

Session title Slides Webcast
Dyslipidaemias part 1    
Dyslipidaemias part 2    
LDL lowering: the evidence    
The new lipid guidelines    
Other lipoproteins do they matter?    
Future challenges    
ESC Clinical practice guidelines 2016. Highlights - Dyslipidaemias    

Part 2 - Topics in focus

Topic/Section Session title Slides Webcast
Prevention and Rehabilitation LDL vs non-HDL cholesterol.Where do we stand?    
Prevention and Rehabilitation New emerging therapies    
Prevention and Rehabilitation Goals, percent reduction or both?    
Prevention and Rehabilitation Familial hypercholesterolaemia, underdiagnosed and undertreated condition    
Prevention and Rehabilitation Utility of apoB target over LDL-C and non-HDL-C targets: insights from the national health and nutrition examination survey    
Prevention and Rehabilitation Familial hypercholesterolaemia diagnosis: a case of missed opportunity    
Prevention and Rehabilitation A naturally randomised trial comparing the effect of long-term exposure to lower LDL-C, lower SBP or both on the risk of cardiovascular disease    
Basic Science Low levels of LDL-cholesterol and incidence of a wide range of cardiovascular disease: a linked electronic health records cohort of 550 000 people    
Acute Coronary Syndrome The benefit of adding ezetimibe to statin therapy in patients with and without prior coronary artery bypass graft surgery in the IMPROVE_IT trial    
Prevention and Rehabilitation Current evidence and best practice for lipid management in young adults. State of the art    
Interventional Cardiology and Surgery Advances in the treatment of dyslipidaemias    
Prevention and Rehabilitation Decline over the years in the risk of cardiovascular events in patients with the clinically manifest vascular disease is explained by a change in CV risk factors and atherosclerotic burden    
Prevention and Rehabilitation Do we need to worry about HDL?